Fused MGL Modulators for Selective 2-AG Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders associated with MGL receptor activity, such as depression, anxiety, PTSD, pain, and cancer, often have side effects due to the broad modulation of the cannabinoid system by CB1 agonists, and there is a need for targeted MGL modulation to minimize these effects.
Innovation Solution
Development of fused chemical entities that modulate MGL activity, including inhibitors, to selectively enhance 2-AG levels and attenuate proinflammatory cascades, providing therapeutic benefits without the full spectrum of neurobehavioral effects of CB1 agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 agonists are used to modulate the cannabinoid system, then therapeutic effects are achieved, but side effects occur due to broad modulation
Solution Approach 1:
The patent extracts and targets only the specific enzyme MGL for inhibition, rather than using broad-spectrum CB1 agonists. This selective extraction of the therapeutic target allows achieving therapeutic effects through 2-AG elevation without the broad modulation side effects of CB1 agonists
Solution Approach 2:
The patent uses MGL inhibitors as an intermediary mechanism to indirectly elevate 2-AG levels and activate CB1 receptors, rather than directly administering CB1 agonists. This intermediary approach achieves the desired cannabinoid system modulation while avoiding direct agonist side effects
2Object-affected harmful factors
If MGL inhibitors are used to selectively enhance 2-AG levels, then side effects are minimized, but targeted delivery to specific brain regions is challenging
Solution Approach 1:
The patent exploits the local quality difference that MGL is specifically expressed in brain regions with high CB1 receptor density and active endocannabinoid production. By targeting MGL, the therapy automatically concentrates its effect in these specific brain regions rather than uniformly affecting the entire brain
Solution Approach 2:
The patent leverages the endogenous 2-AG production mechanism in specific brain regions. MGL inhibitors work where 2-AG is naturally produced and needed, allowing the body's own endocannabinoid system to self-regulate in the appropriate locations without external targeting mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MGL modulators effectively treat a range of conditions, including mood disorders, pain, inflammatory diseases, cancer, and eye conditions, while minimizing side effects by selectively targeting brain regions with active endocannabinoid production.
Implementation Method 1
Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol
Data Source
AI summary
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.